CYCC - Cyclacel Pharmaceuticals, Inc.
IEX Last Trade
0.324
0 0%
Share volume: 0
Last Updated: Thu 26 Dec 2024 02:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.32
0.00
0.00%
Fundamental analysis
25%
Profitability
25%
Dept financing
4%
Liquidity
50%
Performance
25%
Performance
5 Days
-2.40%
1 Month
-10.28%
3 Months
-68.24%
6 Months
-83.28%
1 Year
-88.70%
2 Year
-97.11%
Key data
Stock price
$0.32
DAY RANGE
$0.31 - $1.00
52 WEEK RANGE
$0.32 - $4.00
52 WEEK CHANGE
-$88.82
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Spiro Rombotis
Region: US
Website: cyclacel.com
Employees: 14
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cyclacel.com
Employees: 14
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Cyclacel Pharmaceuticals, Inc. develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) and CYC140. Sapacitabine, a nucleoside analog that is orally available prodrug of CNDAC, is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome.
Recent news